JPWO2021161876A1 - - Google Patents

Info

Publication number
JPWO2021161876A1
JPWO2021161876A1 JP2022500348A JP2022500348A JPWO2021161876A1 JP WO2021161876 A1 JPWO2021161876 A1 JP WO2021161876A1 JP 2022500348 A JP2022500348 A JP 2022500348A JP 2022500348 A JP2022500348 A JP 2022500348A JP WO2021161876 A1 JPWO2021161876 A1 JP WO2021161876A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2022500348A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021161876A1 publication Critical patent/JPWO2021161876A1/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022500348A 2020-02-10 2021-02-03 Abandoned JPWO2021161876A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020020621 2020-02-10
PCT/JP2021/003981 WO2021161876A1 (ja) 2020-02-10 2021-02-03 ベンダムスチン液剤

Publications (1)

Publication Number Publication Date
JPWO2021161876A1 true JPWO2021161876A1 (pl) 2021-08-19

Family

ID=77291841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500348A Abandoned JPWO2021161876A1 (pl) 2020-02-10 2021-02-03

Country Status (2)

Country Link
JP (1) JPWO2021161876A1 (pl)
WO (1) WO2021161876A1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518130A (ja) * 2010-01-28 2013-05-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
JP2015127300A (ja) * 2013-12-27 2015-07-09 富士フイルム株式会社 注射液製剤及びその製造方法
JP2019099557A (ja) * 2017-11-28 2019-06-24 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
JP2020090481A (ja) * 2018-11-27 2020-06-11 日本化薬株式会社 ベンダムスチンを含有する溶液製剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2827863B1 (en) * 2012-03-20 2019-01-16 Eagle Pharmaceuticals, Inc. Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518130A (ja) * 2010-01-28 2013-05-20 イーグル・ファーマシューティカルズ・インコーポレーテッド ベンダムスチンの製剤
JP2015127300A (ja) * 2013-12-27 2015-07-09 富士フイルム株式会社 注射液製剤及びその製造方法
JP2019099557A (ja) * 2017-11-28 2019-06-24 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
JP2020090481A (ja) * 2018-11-27 2020-06-11 日本化薬株式会社 ベンダムスチンを含有する溶液製剤

Also Published As

Publication number Publication date
WO2021161876A1 (ja) 2021-08-19

Similar Documents

Publication Publication Date Title
BR112023005462A2 (pl)
BR112023012656A2 (pl)
BR112021014123A2 (pl)
BR112022009896A2 (pl)
BR112023009656A2 (pl)
BR112022024743A2 (pl)
BR112023006729A2 (pl)
BR102021018859A2 (pl)
BR102021015500A2 (pl)
BR112023008622A2 (pl)
BR112023011738A2 (pl)
BR112023016292A2 (pl)
BR112023004146A2 (pl)
BR112023011539A2 (pl)
BR112023011610A2 (pl)
BR112023008976A2 (pl)
BR102021020147A2 (pl)
BR102021018926A2 (pl)
BR102021018167A2 (pl)
BR102021017576A2 (pl)
BR102021016837A2 (pl)
BR102021016551A2 (pl)
BR102021016375A2 (pl)
BR102021016200A2 (pl)
BR102021016176A2 (pl)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20230501